CERC-301

CERC-301

Names
IUPAC name 4-Methylbenzyl (3S,4R)-3-fluoro-4-[(2-pyrimidinylamino)methyl]-1-piperidinecarboxylate
Identifiers
ChemSpider	9569140
Jmol 3D model	Interactive image
PubChem	11394238
UNII	5HAM167S5T
InChI InChI=1S/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1 Key: RECBFDWSXWAXHY-IAGOWNOFSA-N InChI=1/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1 Key: RECBFDWSXWAXHY-IAGOWNOFBJ
SMILES CC1=CC=C(C=C1)COC(=O)N2CC[C@@H]([C@@H](C2)F)CNC3=NC=CC=N3
Properties
Chemical formula	C19H23FN4O2
Molar mass	358.42 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

CERC-301 (formerly known as MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD).^[1] In November 2013, phase II clinical trials were initiated,^[2] and in the same month, CERC-301 received Fast Track Designation from the Food and Drug Administration for TRD.^[3]

A pilot study was published in 2012,^[1] and a phase 2 trial was completed in 2014.^[4]

See also

• Esketamine
• Rapastinel
• NRX-1074
• AV-101
• ALKS-5461
• NSI-189

References

1. Ibrahim L, Diaz Granados N, Jolkovsky L; et al. (August 2012). "A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder". J Clin Psychopharmacol 32 (4): 551–7. doi:10.1097/JCP.0b013e31825d70d6. PMC 3438886. PMID 22722512.
2. Yahoo! Finance (2013). "Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate".
3. Yahoo! Finance (2013). "Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder".
4. "A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment". Retrieved 2015-01-04.

External links

• CERC-301 - Cerecor, Inc.